| Literature DB >> 35268367 |
Tsu-Chen Lin1, Po-Chih Chang1,2, I-Hung Shao1,2, Yu Chen1,2, Hsin-Chieh Huang1,2, Yu-Chao Hsu1,2, Ming-Li Hsieh1,2.
Abstract
Benign prostate hyperplasia (BPH) refers to the nonmalignant enlargement of the transition zone of the prostate gland. While holmium laser enucleation of the prostate and open simple prostatectomy are effective in the management of patients with large prostates, they have some limitations. Thus, this study aimed to analyze the efficacy and safety of the sandwich method of bipolar transurethral resection of the prostate (B-TURP) and GreenLight photoselective vaporization of the prostate (GLPVP) in patients with large prostates. Patients diagnosed with BPH who underwent the sandwich method with B-TURP and GLPVP from 2015 to 2020 were included. Efficacy analyses included the change in the uroflowmetry results in both group A (prostate volume < 80 g) and group B (prostate volume ≥ 80 g), and complication analyses included perioperative complications, early postoperative complications at three months and late postoperative complications at 12 months. The cohort comprised 188 and 44 patients in groups A and B, respectively. The prostate volume of groups A and B were 50.83 ± 14.14 g and 102.03 ± 19.36 g (p < 0.001), respectively. The peak (Qmax) and average (Qavg) flow rates were comparable between the two groups. The only significant difference noted was in the postoperative post-void residual (PVR) urine. Improvement was seen in all the variables including the Qmax, Qavg and PVR urine in each group. No patient experienced perioperative complications. Analysis of the overall one-year complication rate showed no significant difference between the two groups. The sandwich method of B-TURP and GLPVP may be feasible for the management of patients with large prostate.Entities:
Keywords: GreenLight photoselective vaporization of the prostate; benign prostate hyperplasia; bipolar-transurethral resection of the prostate; large prostate; transurethral surgery of prostate
Year: 2022 PMID: 35268367 PMCID: PMC8910987 DOI: 10.3390/jcm11051276
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Patient Characteristics.
| Variables | Group A ** | Group B ** | |
|---|---|---|---|
| Age (Mean ± SD) (years) | 69.06 ± 7.82 | 69.25 ± 6.07 | 0.859 |
| Gender, Male, | 188 (100%) | 44 (100%) | |
| BMI, (Mean ± SD) (kg/m2) | 24.79 ± 3.42 | 25.73 ± 3.23 | 0.101 |
| Social History, | |||
| Alcohol Consumption | 25 (13.3%) | 5 (11.4%) | 0.669 |
| Betel Nut Use | 12 (6.4%) | 6 (13.6%) | 0.123 |
| Cigarette Use | 43 (22.9%) | 13 (29.5%) | 0.411 |
| Preoperative IPSS | 23.55 ± 4.40 | 23.83 ± 4.50 | 0.754 |
| Comorbidities, | |||
| Hypertension | 76 (40.4%) | 24 (54.5%) | 0.089 |
| Diabetes Mellitus | 32 (17.0%) | 7 (15.9%) | 0.859 |
| Gastrointestinal Disorders | 18 (9.6%) | 2 (4.5%) | 0.381 |
| Dyslipidemia | 12 (6.4%) | 4 (9.1%) | 0.513 |
| Coronary Artery Disease | 13 (6.9%) | 1 (2.3%) | 0.479 |
| Prostate Volume (g) | 50.83 ± 14.14 | 102.03 ± 19.36 | <0.001 * |
| Prostate Transitional Zone Size (g) | 24.41 ± 11.00 | 50.81 ± 15.73 | <0.001 * |
* p-value < 0.05; ** Group A: Prostate volume < 80 g; Group B: Prostate volume ≥ 80 g; BMI: Body mass index; SD: Standard deviation; IPSS: International prostate symptom score.
Biochemical Values.
| Variables | Group A ** | Group B ** | |
|---|---|---|---|
| Preoperative | |||
| Total PSA (ng/mL) | 6.29 ± 5.68 | 12.79 ± 14.56 | 0.012 * |
| Postoperative | |||
| Total PSA (ng/mL) | 3.33 ± 3.09 | 6.09 ± 3.60 | <0.001 * |
* p-value < 0.05; ** Group A: Prostate volume < 80 g; Group B: Prostate volume ≥ 80 g; PSA: Prostate specific antigen.
Uroflowmetry between different prostate volume.
| Variables | Group A ** | Group B ** | |
|---|---|---|---|
| Preoperative | |||
| Qmax (mL/s) | 9.26 ± 7.22 | 8.07 ± 3.01 | 0.379 |
| Qavg (mL/s) | 3.46 ± 1.87 | 3.07 ± 1.17 | 0.152 |
| PVR | 125.88 ± 166.99 | 102.77 ± 76.76 | 0.258 |
| Postoperative | |||
| Qmax (mL/s) | 16.05 ± 8.48 | 14.32 ± 7.52 | 0.250 |
| Qavg (mL/s) | 7.37 ± 4.20 | 6.05 ± 3.61 | 0.077 |
| PVR | 32.30 ± 45.02 | 53.33 ± 39.23 | 0.008 * |
* p-value < 0.05; ** Group A: Prostate volume < 80 g; Group B: Prostate volume ≥ 80 g; Qmax: Peak flow rate; Qavg: Average flow rate; PVR: Postvoid residual.
Uroflowmetry in different prostate volume.
| Variables | Preoperative | Postoperative | |
|---|---|---|---|
| Group A ** | |||
| Qmax (mL/s) | 9.53 ± 7.63 | 16.07 ± 8.39 | <0.001 * |
| Qavg (mL/s) | 3.53 ± 1.88 | 7.39 ± 4.27 | <0.001 * |
| PVR | 131.89 ± 176.28 | 25.60 ± 32.64 | 0.001 * |
| Group B ** | |||
| Qmax (mL/s) | 7.92 ± 3.16 | 14.12 ± 8.00 | <0.001 * |
| Qavg (mL/s) | 3.00 ± 1.23 | 5.92 ± 3.77 | <0.001 * |
| PVR | 104.35 ± 81.66 | 49.08 ± 34.52 | 0.001 * |
* p-value < 0.05; ** Group A: Prostate volume < 80 g; Group B: Prostate volume ≥ 80 g; Qmax: Peak flow rate; Qavg: Average flow rate; PVR: Postvoid residual.
Complications.
| Variables | Group A * | Group B * | |
|---|---|---|---|
| Perioperative | |||
| TUR Syndrome | 0 | 0 | |
| Blood Transfusion | 0 | 0 | |
| Capsular Perforation | 0 | 0 | |
| ER Visit-1 year | 15 | 4 | 0.765 |
| Readmission-1 year | 9 | 2 | 1.000 |
| Reintervention-1 year | 9 | 2 | 1.000 |
| BPH Recurrence | 0 | 1 | 0.190 |
| Urethral Stricture | 3 | 1 | 0.571 |
| Bladder Neck Stenosis | 5 | 0 | 0.586 |
| Hematuria | 1 | 0 | 1.000 |
| Incontinence | 0 | 0 | |
| Early Complications ** | |||
| ER Visit | 13 | 2 | 0.742 |
| Readmission | 5 | 2 | 0.620 |
| Reintervention | 3 | 2 | 0.241 |
| Late Complications ** | |||
| ER Visit | 2 | 2 | 0.165 |
| Readmission | 4 | 0 | 1.000 |
| Reintervention | 6 | 0 | 0.598 |
* Group A: Prostate volume < 80 g; Group B: Prostate volume ≥ 80 g; ** Early complications: 0–3 months; Late complications: 4–12 months.